Long-term atorvastatin-ezetimibe-probucol triple therapy for homozygous familial hypercholesterolaemia from early childhood.

Abstract

In this observational case report, we share our experience of achieving >40% LDL cholesterol reduction in four Chinese homozygous familial hypercholesterolaemia children below 8 years of age with a triple combination of atorvastatin, probucol, and ezetimibe for >6 years. Within a follow-up duration of 6-13 years, this triple therapy achieved significant reduction of LDL cholesterol as well as an impressive regression of xanthomas in all paediatric cases. All the children remained free from treatment-related adverse responses and cardiovascular events throughout follow-up.

• Authors: Minjie Lin, Helong Dai, Shuiping Zhao
• Journal: Cardiology in the young (Cardiol Young) Vol. 26 Issue 1 Pg. 197-201 (Jan 2016) ISSN: 1467-1107 [Electronic] England
• PMID: 25907359 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anticholesteremic Agents
• Atorvastatin
• Ezetimibe
• Probucol

Topics

• Anticholesteremic Agents (administration & dosage)
• Atorvastatin (administration & dosage)
• Child
• Child, Preschool
• Drug Therapy, Combination
• Ezetimibe (administration & dosage)
• Female
• Follow-Up Studies
• Homozygote
• Humans
• Hyperlipoproteinemia Type II (drug therapy, genetics)
• Male
• Probucol (administration & dosage)
• Time Factors